Hepatitis A Hospitalization Costs, United States, 2017

Hofmeister, Megan G.; Yin, Shaoman; Aslam, Maria; Teshale, Eyasu H.; Spradling, Philip R.

doi:10.3201/eid2605.191224

Cited by 15 publications

(14 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 The average cost of a hepatitis A-related hospitalization in 2016 was $16 610, and recent hepatitis A virus outbreaks alone have cost the nation at least $270 million since 2016. 19 In 2019, HIV care and treatment cost the US government more than $20 billion. 20 The cost for treating HIV infections related to the Scott County outbreak is projected to be more than $100 million.…”

Section: Making the Case For Syringe Services Programsmentioning

confidence: 99%

Making the Case for Syringe Services Programs

Adams¹

2020

Public Health Rep

View full text Add to dashboard Cite

Section: Making the Case For Syringe Services Programsmentioning

confidence: 99%

Making the Case for Syringe Services Programs

Adams¹

2020

Public Health Rep

View full text Add to dashboard Cite

“…In this study, the average costs of a HAV infection-related hospitalization were $246, while in the United States, in 2017, the average costs were $16,232 (21). Cost-effective analyses performed in Ireland also showed that where HAV immunity is 45% or less, vaccination is the strategy of choice without a prior screening (22).…”

Section: Discussionmentioning

confidence: 64%

Ulusal aşı programı ve kitlesel göçün, 2013-2018 arasında çocuklarda hepatit A epidemiyolojisine etkileri

Çetin

2022

Journal of Medicine and Palliative Care

View full text Add to dashboard Cite

Aim: Acute hepatitis A is a common public health problem in underdeveloped and developing countries. The hepatitis A vaccine was implemented as part of the National Immunization Program in Turkey in November 2012. The present study aimed to investigate the effects of the national vaccination program and massive migration on the epidemiology and clinical burden of hepatitis A infection. Material and Method: The study was a single center, retrospective chart review study among children diagnosed with viral hepatitis A infection between 0 and 18 years of age from January 2013 to February 2018 in Gaziantep Cengiz Gökçek Maternity and Children Hospital, Turkey. All cases’ age, diagnosis time, nationality, and gender information were evaluated. The length of stay, the maximum value of alanine transaminase and aspartate aminotransferase, and the direct medical cost of hospitalization were also evaluated in hospitalized cases. Results: During the study period total of 1039 cases were diagnosed with hepatitis A infection. Of these cases, 53% were males, 14% were Syrian refugees, and the median age was 7.9-year. The number of cases per year (2013 through 2017) was 321, 360, 157, 119, and 73, respectively. The majority of the cases were detected in November, December, and January. While the total number of cases was declining, we saw that the number of Syrian cases was increasing. The percentage of Syrian children in total cases in 2013 and 2017 was 6.5% and 52.1%, respectively. The hospitalization rate was %49.4, the median length of stay was four days, and the average medical cost of hospitalization was 246.8$/case. Conclusion: With the national vaccination program, prevalence is declining, but the number of susceptible individuals in society is still adversely affecting the epidemiology of the disease. Continuous monitoring of epidemiological data and efforts to expand vaccine coverage are required for infection control.

show abstract

“…We adopted a limited societal perspective in estimating costs, which incorporated the direct medical costs and nonmedical costs (i.e., public health costs and productivity loss due to illness). The direct medical costs included outpatient and inpatient costs of clinical management of HAV infection, vaccine and vaccine administration costs, and the cost of postvaccination serologic testing for HAV immunity [6][7][8][9][10][11]. We included the full cost of the 3-dose hepatitis A and hepatitis B combination vaccine and the 2-dose hepatitis A single-antigen vaccine.…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of expanded hepatitis A vaccination among adults with diagnosed HIV, United States

et al. 2023

View full text Add to dashboard Cite

Hepatitis A virus can cause severe and prolonged illness in persons with HIV (PWH). In July 2020, the Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for hepatitis A vaccination to include all PWH aged ≥1 year. We used a decision analytic model to estimate the value of vaccinating a cohort of adult PWH aged ≥20 years with diagnosed HIV in the United States using a limited societal perspective. The model compared 3 scenarios over an analytic horizon of 1 year: no vaccination, current vaccine coverage, and full vaccination. We incorporated the direct medical costs and nonmedical costs (i.e., public health costs and productivity loss). We estimated the total number of infections averted, cost to vaccinate, and incremental cost per case averted. Full implementation of the ACIP recommendation resulted in 775 to 812 fewer adult cases of hepatitis A in 1 year compared with the observed vaccination coverage. The incremental cost-effectiveness ratio for the full vaccination scenario was $48,000 for the 2-dose single-antigen hepatitis A vaccine and $130,000 for the 3-dose combination hepatitis A and hepatitis B vaccine per case averted, compared with the observed vaccination scenario. Depending on type of vaccine, full hepatitis A vaccination of PWH could lead to ≥80% reduction in the number of cases and $48,000 to $130,000 in additional cost per case averted. Data on hepatitis A health outcomes and costs specific to PWH are needed to better understand the longer-term costs and benefits of the 2020 ACIP recommendation.

show abstract

Hepatitis A Hospitalization Costs, United States, 2017

Cited by 15 publications

References 1 publication

Making the Case for Syringe Services Programs

Making the Case for Syringe Services Programs

Ulusal aşı programı ve kitlesel göçün, 2013-2018 arasında çocuklarda hepatit A epidemiyolojisine etkileri

Cost-effectiveness of expanded hepatitis A vaccination among adults with diagnosed HIV, United States

Contact Info

Product

Resources

About